



Date	Friday, May 21, 2021			
Topic	Muscle Disorders			
Time (CEST)	Presentation Title	Speaker	Speaker Country	Session Chair
Industry Supported Symposia 12:00-12:45				
Opening Session: 13:00-14:00	Opening	Juan Vilchez	Spain	
SS 1.0 News on FSHD 14:00-15:00	FSHD: Setting the Stage	George Padberg	Netherlands	George Padberg, Netherlands
	FSHD: Genetics, Epigenetics and Genetic diagnosis	Stephen Tapscott	USA	
	FSHD: Biomarkers, outcome measures and therapies	Nicol Voermans	Netherlands	
WS 1.0 Muscle Biopsy 14:00-15:00	Immune myopathies: New syndromes	Alan Pestronk	USA	Alan Pestronk, USA
	Dermatomyositis	Ichizo Nishino	Japan	
SS 2.0 Metabolic muscle diseases 15:00 - 16:00	Novel therapies in mitochondrial disorders	Jochen Schafer	Germany	Antonio Toscano, Italy & Pascal Laforêt, France
	Novel suggestions in treatment of muscle glycogenoses	Antonio Toscano	Italy	
	Emerging clinical entities in metabolic myopathies	Pascal Laforet	France	
WS 2.0 News in Muscle Imaging MRI 15:00 - 16:00	Visual representations of muscle MRI data	David Gómez Andres	Spain	Susana Quijano-Roy, France & Jordi Díaz- Manera, Spain
	Unravelling patterns of muscle involvement in distal myopathies	Giorgio Tasca	Italy	
	Follow-up of muscle degeneration using quantitative muscle MRI	Pierre Carlier	France	
SS 3.0 Myotonic syndromes at the edge to fundamental treatment 16:15 - 17:15	Non dystrophic myotonias	Giovanni Meola	Italy	Benedikt Schöser, Germany & Giovanni Meola, Italy
	Natural history and outcomes in DM1	Cynthia Gagnon	Canada	
	DM2 standard therapies	Benedikt Schöser	Germany	
WS 3.0 Distal and myofibrillar myopathies update 16:15 - 17:15	New genes causing distal myopathies	Bjarne Udd	Finland	Bjarne Udd, Finland & Nigel Laing, Australia
	Distal myopathy caused myosin and thin filament nebulin	Nigel Laing	Australia	
Industry Supported Symposia: 17:15 - 18:00				



Date	Saturday, May 22, 2021			
Topic	Peripheral Neuropathies			
Time (CEST)	Presentation Title	Speaker	Speaker Country	Session Chair
Industry Supported Symposia 12:00-12:45				
SS 4.0 PNS-ICNMD: Recent therapeutic advances 13:00 - 14:00	TRR Amyloidosis	Laura Obici	Italy	Charlotte Sumner, USA
	SMA	Charlotte Sumner	USA	
	CMT: new treatment concepts and pathways	Alessandra Bolino	Italy	
WS 4.0 Paraneoplastic Neuropathies 13:00 - 14:00	Overview on Paraneoplastic Neuropathies	Francesc Graus	Spain	Francesc Graus, Spain
	Paraneoplastic Sensory Neuronopathy	Jean-Christophe Antoine	France	
	Paraneoplastic Neuromyotonia	Luis Bataller	Spain	
SS 5.0 Guillain-Barré syndrome and Chronic inflammatory demyelinating polyradiculoneuropathy 14:00 - 15:00	EAN/PNS guideline on diagnosis and management of Guillain-Barré syndrome	Pieter Van Doorn	Netherlands	Eduardo Nobile-Orazio, Italy
	Acute and chronic inflammatory neuropathies and COVID-19	Eduardo Nobile-Orazi	Italy	
	EAN/PNS guideline on diagnosis and management of chronic inflammatory demyelinating polyradiculoneuropathy - Second revision	Peter Van den Bergh	Belgium	
WS 5.0 Nerve biopsy 14:00 - 15:00	From nerve to roots	Peter James B Dyck Jr	USA	Peter James Dyck Jr, USA & Jean-Michel Vallat, France
	When to do and how to do	Jean-Michel Vallat	France	
	Pathology of the nodal complex in CIDP	Haruki Koike	Japan	
SS 6.0 Genetic Neuropathies 15:00 - 16:00	CMT Approach to diagnosis	Davide Pareyson	Italy	Davide Pareyson, Italy
	Autosomal recessive CMT	Teresa Sevilla	Spain	
	Early diagnosis of hATTR neuropathy	Teresa Coelho	Portugal	
WS 6.0 Skin Biopsy 15:00 - 16:00	Clinical indications and normative reference values	Giuseppe Lauria	Italy	Giuseppe Lauria, Italy
	Clues on degeneration and regeneration of somatic and autonomic nerves	Maria Nolano	Italy	
Industry Supported Symposia: 16:15 - 17:00				



Date	Friday, May 28, 2021			
Topic	Neuromuscular Junction Disorders			
Time (CEST)	Presentation Title	Speaker	Speaker Country	Session Chair
Industry Supported Symposia: 12:00-12:45				
SS 7.0 MG: Special Clinical Presentations 13:00 - 14:00	Early onset and Juvenile Myasthenia Gravis	Rozen Le Panse	France	Amelia Evoli, Italy
	Ocular Myasthenia Gravis	Jeannine M. Heckmann	South Africa	
	Myasthenia Gravis in seniors	Elena Cortes	Spain	
WS 7.0 Advances in Dystrophinopathies 13:00 - 14:00	Cardiorespiratory Progression in Duchenne Muscular Dystrophy	Federica Trucco	Italy	Francesco Muntoni, UK
	Dystrophin quantification in diagnostic pathology and clinical trials: implication for diagnosis and translational research	Virginia Arechavala-Gomez	Spain	
	The role of gene modifiers in DMD	Elena Pegoraro	Italy	
SS 8.0 Therapy 14:00 - 15:00	Immunoactive drug therapy	Nils Erik Gilhus	Norway	Nils Erik Gilhus, Norway
	Antisense, RNA silence and other potentials gene therapies in MG	Henry Kaminski	USA	
	Physical training and exercise as treatment for MG	Anna Punga	Sweden	
WS 8.0 Update in Congenital Myopathies 14:00 - 15:00	Triadopathies	Jocelyn Laporte	France	Carsten Bornemann, USA & Ana Ferreiro, France
	Sarcomeropathies	Carsten Bönemann	USA	
	Congenital Myopathies Across the Ages	Ana Ferreiro	France	
SS 9.0 Autoantibodies in Myasthenia Gravis 15:00 - 16:01	MuSK antibodies	Jan Verschuuren	Netherlands	Angela Vincent, UK
	Maternal antibodies – long-term and short-term effects	Angela Vincent	UK	
WS 9.0 Latest discoveries in CMS genes and pathways 15:00 - 16:00	CMS related to glycosylation disorders	Hanns Lochmüller	Canada	Hanns Lochmüller, Canada
	Extracellular matrix in myasthenic syndromes	Pedro Rodriguez-Cruz	UK	
	Mitochondrial pathology in myasthenic syndromes	Rita Horvath	UK	
Industry Supported Symposia: 16:15 - 17:00				



Date	Saturday, May 29, 2021			
Topic	Motor Neuron Diseases			
Time (CEST)	Presentation Title	Speaker	Speaker Country	Session Chair
Industry Supported Symposia: 12:00-12:45				
SS 10.0 Advances in ALS therapy 13:00 - 14:00	Advances in the clinical diagnosis and biomarkers in ALS. Are they ready for clinical trials?	Leonard Van Den Berg	Netherlands	Leonard Van Den Berg, Netherlands
	New Therapies for ALS	Merit Cudkowicz	USA	
	Antisense & siRNA Therapies	Timothy Miller	USA	
WS 10.0 Biomarkers in Motor Neuron Diseases 13:00 - 14:00	Neurophysiology	Christoph Neuwirth	Switzerland	Martin Turner, UK
	CSF Markers	Martin Turner	UK	
SS 11.0 The ALS-FTD continuum 14:00 - 15:00	Cognitive and Behavioural Impairment in ALS	Eneida Mioshi	UK	Matthew Kiernan, Australia
	Motor Symptoms and Signs in FTD	Emma Devenney	Australia	
	Genetic and Pathologic Overlap	Matthew Kiernan	Australia	
WS 11.0 Non-5q SMA 14:00 - 15:00	Tubulinopathies as neurodegenerative disease	Enrico Bertini	Italy	Enrico Bertini, Italy
	Developing treatment for SMARD1	Stefania Corti	Italy	
	Developing treatment for Brown-Vialetto-Van Laere Syndrome	Manoj Menezes	Australia	
SS 12.0 Changing the natural history of SMA 15:00 - 16:00	Natural history of SMA	Eugenio Mercuri	Italy	Eugenio Mercuri, Italy
	SMA registries: what, when and how to register?	Janbernd Kirschner	Germany	
	New treatments in adult SMA: evidences from the clinical practice	Tim Hagenacker	Germany	
WS 12.0 ALS management & palliative care 15:00 - 16:00	Multidisciplinary approach of ALS	Orla Hardiman	Ireland	Orla Hardiman, Ireland
	Technology to improve technical care and trials in MND	Christopher McDermott	UK	
	Palliative care	David Oliver	UK	
Closing Session: 16:15 - 17:15	Closing	Juan Vilchez	Spain	
Industry Supported Symposia: 17:15 - 18:00				